Then apply for the Terra Summer Residency program for Artists and Art Scholars in Giverny, France.
Each summer, the Terra Foundation for American Art offers ten residential fellowships for emerging artists and predoctoral scholars in a setting rich in art historical significance.
Since 2001, the Terra Summer Residency has provided fellows with the opportunity to pursue individual work and research within a framework of interdisciplinary exchange and cross-cultural dialogue. In addition to working collaboratively, fellows interact regularly with invited senior advisors and guest lecturers—established international artists, curators, and professors in the field of American art.
The program supports the creative and research projects of the residents, inspiring them to reflect on cultural interpretive models and encouraging them to create an intellectual network for lifelong exchange.
To apply, click here.
LOI due: December 6, 2013
Proposal due: January 6, 2013
This Funding Opportunity Announcement (FOA) is a new initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs.
Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism. Applicants should have a working assay or prototype (not necessarily already capable of cancer applications). The initial 2-year (or shorter) UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones. UH2 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. The project period for the UH3 phase is up to 3 years. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both UH2 and UH3 phases.